Alchemia wins patents for generic fondaparinux
Wednesday, 25 June, 2008
Alchemia (ASX: ACL) has been granted patents for two of its family of the synthetic heparin oligosaccharides used in its fondaparinux synthesis production method.
Two of its other patent applications have been approved but not yet finalised.
The patents will grant legal protection to Alchemia's method of synthesising fondaparinux sodium up until the year 2022.
Alchemia, and its manufacturing partner Dr Reddy's, hope to go to market in 2009.
Fondaparinux is an anticoagulant medication,generally used subcutaneously daily, particularly in the treatment of deep-vain thrombosis and in those recovering from orthopaedic surgery.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
